Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma

[1]  Steven L. Chang,et al.  Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma , 2021, Nature Communications.

[2]  T. Choueiri,et al.  A Randomized Phase II Study of AGS-16C3F Versus Axitinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma. , 2020, The Oncologist.

[3]  W. Kaelin,et al.  Targeting the HIF2–VEGF axis in renal cell carcinoma , 2020, Nature Medicine.

[4]  C. Porta,et al.  Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial , 2020, Journal for ImmunoTherapy of Cancer.

[5]  B. Escudier,et al.  Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma , 2020, Drugs.

[6]  M. Atkins,et al.  Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Loise M. Francisco,et al.  The PD-1 Pathway Regulates Development and Function of Memory CD8+ T Cells following Respiratory Viral Infection. , 2020, Cell reports.

[8]  T. Choueiri,et al.  Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma. , 2020, JAMA oncology.

[9]  Ashton C. Berger,et al.  Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma , 2020, Nature Medicine.

[10]  T. Choueiri,et al.  Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma , 2020, Investigational New Drugs.

[11]  T. Powles,et al.  Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426. , 2020, Journal of Clinical Oncology.

[12]  J. Larkin,et al.  Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies. , 2020 .

[13]  Robert W. Hsieh,et al.  Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). , 2020 .

[14]  P. Hegde,et al.  High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade , 2020, Nature Medicine.

[15]  Hongyu Zhao,et al.  Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors , 2020, Nature Medicine.

[16]  T. Choueiri,et al.  IL-8 and cancer prognosis on immunotherapy , 2020, Nature Medicine.

[17]  P. Sears.  epitopes , 2020, Catalysis from A to Z.

[18]  C. Mackall,et al.  The Emerging Landscape of Immune Cell Therapies , 2020, Cell.

[19]  S. Buti,et al.  Nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in pretreated patients (pts) with metastatic renal cell carcinoma (mRCC): First results of phase II NIVES study. , 2020 .

[20]  J. Larkin,et al.  Depth of response (DepOR) analysis and correlation with clinical outcomes from JAVELIN Renal 101. , 2020 .

[21]  Sierra M. Barone,et al.  Targeting metabolic dysregulation of T cells in kidney cancer. , 2020 .

[22]  D. Song,et al.  Combination of dual immune checkpoint inhibition (ICI) with stereotactic radiation (SBRT) in metastatic renal cell carcinoma (mRCC) (RADVAX RCC). , 2020 .

[23]  W. Lowrance,et al.  Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma , 2020, Clinical Cancer Research.

[24]  B. Routy,et al.  New pathways in immune stimulation: targeting OX40 , 2020, ESMO Open.

[25]  M. Loustau.  First CAR-T cell immunotherapy against HLA-G: Targeting a unique ICP and TAA , 2019 .

[26]  A. Kamphorst,et al.  An intra-tumoral niche maintains and differentiates stem-like CD8 T cells , 2019, Nature.

[27]  N. Raje,et al.  Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better? , 2019, Leukemia.

[28]  T. Choueiri,et al.  Adenosine A2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. , 2019, Cancer discovery.

[29]  R. Zagożdżon,et al.  Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer , 2019, Cancers.

[30]  N. Hacohen,et al.  A large peptidome dataset improves HLA class I epitope prediction across most of the human population , 2019, Nature Biotechnology.

[31]  E. Jonasch,et al.  A first-in-human phase I/II trial of the oral HIF-2a inhibitor PT2977 in patients with advanced RCC , 2019, Annals of Oncology.

[32]  T. Powles,et al.  Association between depth of response and overall survival: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 214 , 2019, Annals of Oncology.

[33]  T. Ho,et al.  Safety and efficacy of the oral CXCR4 inhibitor X4P-001 + axitinib in advanced renal cell carcinoma patients: An analysis of subgroup responses by prior treatment , 2019, Annals of Oncology.

[34]  T. Powles,et al.  Treatment-free survival, with and without toxicity, as a novel outcome applied to immuno-oncology agents in advanced renal cell carcinoma , 2019, Annals of Oncology.

[35]  R. Motzer,et al.  Efficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): Subgroup analysis from the phase III JAVELIN renal 101 trial of first-line avelumab plus axitinib (A + Ax) vs sunitinib (S) , 2019, Annals of Oncology.

[36]  Guo Ci Teo,et al.  Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma , 2019, Cell.

[37]  G. Curigliano,et al.  Phase (Ph) II study of MBG453 + spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti–PD-1/L1 therapy , 2019, Annals of Oncology.

[38]  Y. Vugmeyster,et al.  Phase Ib, open-label, dose-escalation study of M9241 (NHS-IL12) plus avelumab in patients (pts) with advanced solid tumours , 2019, Annals of Oncology.

[39]  Junnian Zheng,et al.  CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models , 2019, Journal of immunotherapy.

[40]  W. Sellers,et al.  Metabolomic adaptations and correlates of survival to immune checkpoint blockade , 2019, Nature Communications.

[41]  J. Wolchok,et al.  Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition—A Pooled Analysis of Patients With Advanced Melanoma , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  H. Rammensee,et al.  PD-1 and LAG-3 Dominate Checkpoint Receptor–Mediated T-cell Inhibition in Renal Cell Carcinoma , 2019, Cancer Immunology Research.

[43]  S. Elledge,et al.  T-Scan: A Genome-wide Method for the Systematic Discovery of T Cell Epitopes , 2019, Cell.

[44]  James R. Anderson,et al.  Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. , 2019, The Lancet. Oncology.

[45]  N. Hacohen,et al.  PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance , 2019, Nature Immunology.

[46]  N. Vélez de Mendizábal,et al.  A phase Ia/Ib study of an anti-TIM-3 antibody (LY3321367) monotherapy or in combination with an anti-PD-L1 antibody (LY3300054): Interim safety, efficacy, and pharmacokinetic findings in advanced cancers. , 2019, Journal of Clinical Oncology.

[47]  C. Porta,et al.  Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial , 2019, The Lancet.

[48]  T. Powles,et al.  Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study. , 2019, Journal of Clinical Oncology.

[49]  R. Motzer,et al.  CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features. , 2019, Journal of Clinical Oncology.

[50]  C. Porta,et al.  Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis. , 2019, Journal of Clinical Oncology.

[51]  J. Soria,et al.  Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index , 2019, Clinical Cancer Research.

[52]  David C. Smith,et al.  A phase 1 trial of SGN‐CD70A in patients with CD70‐positive, metastatic renal cell carcinoma , 2019, Cancer.

[53]  Catherine J. Wu,et al.  Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors. , 2019, Cancer discovery.

[54]  T. Powles,et al.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[55]  R. Motzer,et al.  Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[56]  E. Moon,et al.  CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment , 2019, Front. Immunol..

[57]  P. Catalano,et al.  irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial , 2019, Clinical Cancer Research.

[58]  C. Brennan,et al.  Tumor mutational load predicts survival after immunotherapy across multiple cancer types , 2019, Nature Genetics.

[59]  J. Castle,et al.  Actively personalized vaccination trial for newly diagnosed glioblastoma , 2018, Nature.

[60]  Alyssa R. Richman,et al.  Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial , 2018, Nature.

[61]  K. Grønbæk,et al.  Human endogenous retroviruses and their implication for immunotherapeutics of cancer. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[62]  K. Livak,et al.  A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens. , 2018, Blood.

[63]  J. Luke,et al.  Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis , 2018, Clinical Cancer Research.

[64]  S. Signoretti,et al.  Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  T. Choueiri,et al.  Evolving Systemic Treatment Landscape for Patients With Advanced Renal Cell Carcinoma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  N. Rioux-Leclercq,et al.  Non-Clear Cell Renal Cell Carcinomas: From Shadow to Light. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  Sara R. Selitsky,et al.  Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma , 2018, The Journal of clinical investigation.

[68]  A. Tolcher,et al.  Safety, tolerability, and pharmacokinetics of the OX40 agonist ABBV-368 in patients with advanced solid tumors. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[69]  J. Schlom,et al.  First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors , 2018, Clinical Cancer Research.

[70]  L. Emens,et al.  Targeting adenosine for cancer immunotherapy , 2018, Journal of Immunotherapy for Cancer.

[71]  Leonard D. Goldstein,et al.  An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory Factors. , 2018, Cancer discovery.

[72]  J. Larkin,et al.  NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT. , 2018 .

[73]  J. Reeves,et al.  Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma , 2018, Nature Medicine.

[74]  Molly F. Thomas,et al.  Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade , 2018, The oncologist.

[75]  Tyler J. Reich,et al.  Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells , 2018, Nature.

[76]  R. Motzer,et al.  Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas , 2018, Clinical Cancer Research.

[77]  J. Wolchok,et al.  Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. , 2018, Cancer cell.

[78]  Paul T. Spellman,et al.  The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma , 2018, Cell reports.

[79]  Steven J. M. Jones,et al.  The Immune Landscape of Cancer , 2018, Immunity.

[80]  Bohuslav Melichar,et al.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[81]  M. Kunitski,et al.  Double-slit photoelectron interference in strong-field ionization of the neon dimer , 2018, Nature Communications.

[82]  Mark W. Ball,et al.  Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma , 2018, Science.

[83]  R. Kerbel,et al.  Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa , 2018, Nature Reviews Clinical Oncology.

[84]  R. Bourgon,et al.  TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.

[85]  B. Seliger,et al.  T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma—Implications for Adoptive Cell Therapy , 2018, Cancer Immunology Research.

[86]  I. Melero,et al.  Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. , 2018, Blood.

[87]  E. Jaffee,et al.  Tumor Mutational Burden and Response Rate to PD-1 Inhibition. , 2017, The New England journal of medicine.

[88]  Peter K. Sorger,et al.  Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy , 2017, Cell.

[89]  H. Rammensee,et al.  Results of a Phase 1/2 Study in Metastatic Renal Cell Carcinoma Patients Treated with a Patient-specific Adjuvant Multi-peptide Vaccine after Resection of Metastases. , 2017, European urology focus.

[90]  J. Lee,et al.  1141PDCA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in Phase 1 study , 2017 .

[91]  Nicolai J. Birkbak,et al.  Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. , 2017, The Lancet. Oncology.

[92]  Laurence Zitvogel,et al.  The immune contexture in cancer prognosis and treatment , 2017, Nature Reviews Clinical Oncology.

[93]  J. Utikal,et al.  Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer , 2017, Nature.

[94]  Charles H. Yoon,et al.  An immunogenic personal neoantigen vaccine for patients with melanoma , 2017, Nature.

[95]  A. Belldegrun,et al.  Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial , 2017, JAMA oncology.

[96]  E. Schmidt,et al.  Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors , 2017, Clinical Cancer Research.

[97]  W. Rathmell,et al.  Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma. , 2017, JCI insight.

[98]  L. Garraway,et al.  Metabolomic correlates of response in nivolumab-treated renal cell carcinoma and melanoma patients. , 2017 .

[99]  David C. Smith,et al.  Epacadostat plus pembrolizumab in patients with advanced RCC: Preliminary phase I/II results from ECHO-202/KEYNOTE-037. , 2017 .

[100]  A. El-Khoueiry,et al.  The relationship of pharmacodynamics (PD) and pharmacokinetics (PK) to clinical outcomes in a phase I study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600). , 2017 .

[101]  Michael B. Stadler,et al.  An Immune Atlas of Clear Cell Renal Cell Carcinoma , 2017, Cell.

[102]  D. Allard,et al.  Targeting A2 adenosine receptors in cancer , 2017, Immunology and cell biology.

[103]  Guangming Zhou,et al.  Ecto-5′-nucleotidase (CD73) is a biomarker for clear cell renal carcinoma stem-like cells , 2017, Oncotarget.

[104]  A. Badawy.  Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects , 2017, International journal of tryptophan research : IJTR.

[105]  E. Tartour,et al.  Tim-3 Expression on Tumor-Infiltrating PD-1+CD8+ T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma. , 2017, Cancer research.

[106]  I. Diaconu,et al.  Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[107]  Catherine J. Wu,et al.  Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies. , 2017, Cancer journal.

[108]  S. Robson,et al.  The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets , 2017, Immunological reviews.

[109]  P. Validire,et al.  Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma , 2017, Clinical Cancer Research.

[110]  Ludmila V. Danilova,et al.  Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures , 2016, Genome Biology.

[111]  J. Yang,et al.  Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers , 2016, Clinical Cancer Research.

[112]  B. Rini,et al.  IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. , 2016, The Lancet. Oncology.

[113]  R. Ferris,et al.  Phase 1 study of MEDI0562, a humanized OX40 agonist monoclonal antibody (mAb), in adult patients (pts) with advanced solid tumors , 2016 .

[114]  S. Sleijfer,et al.  Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview. , 2016, Biochemical Society transactions.

[115]  W. Oyen,et al.  Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma. , 2016, European urology.

[116]  G. Freeman,et al.  Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model , 2016, Oncotarget.

[117]  P. Hegde,et al.  The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition , 2016, Clinical Cancer Research.

[118]  Zhenjie Wu,et al.  Tim-3 expression represents dysfunctional tumor infiltrating T cells in renal cell carcinoma , 2016, World Journal of Urology.

[119]  Kole T. Roybal,et al.  Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits , 2016, Cell.

[120]  W. Linehan,et al.  Detection of an Immunogenic HERV-E Envelope with Selective Expression in Clear Cell Kidney Cancer. , 2016, Cancer research.

[121]  M. Addepalli,et al.  NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models , 2016, Clinical Cancer Research.

[122]  Nikolaos Diamantis,et al.  Antibody-drug conjugates—an emerging class of cancer treatment , 2016, British Journal of Cancer.

[123]  T. Eleftheriadis,et al.  Indoleamine 2,3‐dioxygenase depletes tryptophan, activates general control non‐derepressible 2 kinase and down‐regulates key enzymes involved in fatty acid synthesis in primary human CD4+ T cells , 2015, Immunology.

[124]  David L Porter,et al.  CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. , 2015, Blood.

[125]  N. Vigneron.  Human Tumor Antigens and Cancer Immunotherapy , 2015, BioMed research international.

[126]  T. Choueiri,et al.  Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma. , 2015, European urology.

[127]  Irene Georgakoudi,et al.  From Shadow to Light , 2015, Surgical innovation.

[128]  G. Freeman,et al.  Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer , 2015, Clinical Cancer Research.

[129]  N. Hacohen,et al.  Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.

[130]  R. Figlin,et al.  The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma , 2014, Clinical Cancer Research.

[131]  O. Hakenberg,et al.  Spontaneous regression of renal cell carcinoma: Reality or myth? , 2014 .

[132]  A. Mayer-Mokler,et al.  IMA901: A multi-peptide cancer vaccine for treatment of renal cell cancer , 2014, Human vaccines & immunotherapeutics.

[133]  B. Becher,et al.  New insights into IL-12-mediated tumor suppression , 2014, Cell Death and Differentiation.

[134]  J. Schlom,et al.  The immunocytokine NHS-IL12 as a potential cancer therapeutic , 2014, Oncotarget.

[135]  B. Fox,et al.  OX40 is a potent immune-stimulating target in late-stage cancer patients. , 2013, Cancer research.

[136]  Adam Bagg,et al.  Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. , 2013, Blood.

[137]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[138]  The Cancer Genome Atlas Research Network.  COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.

[139]  S. Poletajew,et al.  Spontaneous regression of renal cell carcinoma , 2013, Contemporary oncology.

[140]  S. Sleijfer,et al.  Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[141]  Laurence Zitvogel,et al.  Immunogenic cell death in cancer therapy. , 2013, Annual review of immunology.

[142]  K. Yamakado,et al.  Limited expression of cancer-testis antigens in renal cell carcinoma patients. , 2013, Molecular and clinical oncology.

[143]  Tongguang Wang,et al.  Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy , 2013, Journal of immunotherapy.

[144]  Hiroaki Tanaka,et al.  Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival , 2012, Nature Medicine.

[145]  I. Melero,et al.  A Phase I Pharmacologic Study of Necitumumab (imc-11f8), a Fully Human Igg1 Monoclonal Antibody the Hif-1␣ Hypoxia Response in Tumor-infi Ltrating T Lymphocytes Induces Functional Cd137 (4-1bb) for Immunotherapy , 2022 .

[146]  S. Steinberg,et al.  Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2011, Clinical Cancer Research.

[147]  J. Tostain,et al.  Carbonic anhydrase 9 in clear cell renal cell carcinoma: a marker for diagnosis, prognosis and treatment. , 2010, European journal of cancer.

[148]  H. Weiner,et al.  Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell–like and Foxp3+ regulatory T cells , 2010, Nature Immunology.

[149]  B. Escudier,et al.  A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma , 2009, Clinical Cancer Research.

[150]  M. Lerman,et al.  Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show? , 2009, Biochimica et biophysica acta.

[151]  S. Steinberg,et al.  High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma , 2008, Cancer.

[152]  J Philip McCoy,et al.  Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. , 2008, The Journal of clinical investigation.

[153]  Jeffrey W. Clark,et al.  Targeted Agents: The Rules of Combination , 2007, Clinical Cancer Research.

[154]  S. Sleijfer,et al.  Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[155]  F. Peale,et al.  Expression of vascular endothelial growth factor, hypoxia inducible factor 1α, and carbonic anhydrase IX in human tumours , 2004, Journal of Clinical Pathology.

[156]  S. Buisson,et al.  MHC class II signal transduction in human dendritic cells induced by a natural ligand, the LAG-3 protein (CD223). , 2003, Blood.

[157]  D. Vignali,et al.  The CD4‐related molecule, LAG‐3 (CD223), regulates the expansion of activated T cells , 2003, European journal of immunology.

[158]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[159]  K. Toyka,et al.  Therapies , 2002, Journal of the Neurological Sciences.

[160]  W. Linehan,et al.  Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. , 2000, The New England journal of medicine.

[161]  R. Figlin,et al.  Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[162]  R. Figlin,et al.  Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. , 1997, The Journal of urology.

[163]  W. Kaelin,et al.  Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[164]  A. Chang,et al.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. , 1985, The New England journal of medicine.

[165]  T. Choueiri,et al.  Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer , 2019 .

[166]  S. Signoretti,et al.  Chimeric antigen receptor T cells secreting anti-PD-L 1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model , 2016 .

[167]  G. Riethmüller,et al.  Monoclonal antibodies in cancer therapy , 2004, Springer Seminars in Immunopathology.

[168]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.